accounts, page-4

have to agree with you also, the timing of the options granted to the ceo 1 month before Cephalon make the decison whether they want to acquire 20% more is interesting to say the least, though having said that im a little unsure of the recent selling, whether its tree shaking, nervous SH or it has something to do with the recent auditors statement.

Personally i dont think Cephalon would have funded them without thinking they had a real shot at producing sufficent data collection which was the markets sentiment when first announced. With data collection in sights, no problems with the drug (that im aware of) and FDA saying that no extra trials are required then recent SP action is a short term fluctuation unless some people know some things that we dont.